Study Aiming at Researching Diagnostic Markers for the Recognition of Precancerous States, Tracking, Follow-up, and the Identification of New Therapeutic Targets for Mesothelioma in Patients With Atypical Mesothelial Hyperplasia.
Study Aiming at Researching Diagnostic Markers for the Recognition of Precancerous States, Tracking, Follow-up, and the Identification of New Therapeutic Targets for Mesothelioma in Patients With Atypical Mesothelial Hyperplasia.
RATIONALE: Studying levels of mesothelin and osteopontin in samples of blood from patients with mesothelioma or atypical mesothelial hyperplasia may help doctors identify biomarkers related to cancer.
PURPOSE: This research study is looking at mesothelin and osteopontin as diagnostic markers in patients with mesothelioma or atypical hyperplasia.
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a multicenter study.
Levels of mesothelin and osteopontin in serum (and pleural fluid, if effusion is present) are measured at baseline and 3, 6, 12, and 24 months. Patients with mesothelioma, reactional lesions, or adenocarcinoma undergo tomodensitometry (TDM) at baseline, 3, 6, and 12 months. Patients with pleural plaques only undergo TDM at 12 months.
Patients are followed for 5 years.
DISEASE CHARACTERISTICS:
Inclusion criteria:
Diagnosis of mesothelial hyperplasia and meeting 1 of the following criteria:
Confirmed prior exposure to asbestos and presence of pleural effusion and meets 1 of the following diagnostic criteria:
No asbestos exposure but pleural effusion with pleural malignant mesothelioma or pulmonary metastasis
Prior exposure to asbestos, no pleural effusion, and asymptomatic (pleural plaques present)
No prior exposure to asbestos but with benign pleural effusion
Tissue obtained by pleuroscopy, surgical biopsy, or video-thoracoscopy available
Exclusion criteria:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY: